INCYTE CORPORATION (INCY) Shareholder Equity
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $200.00K; Additional Paid in Capital, Common StockUSD $5.08B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $22.31M.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $198.00K; Additional Paid in Capital, Common StockUSD $4.93B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $25.46M.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $196.00K; Additional Paid in Capital, Common StockUSD $4.72B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $14.55M.
- 2025-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $194.00K; Additional Paid in Capital, Common StockUSD $4.67B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $13.44M.
INCYTE CORPORATION Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Treasury Stock Acquired, Average Cost Per Share USD/shares | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt USD | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation USD |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | $0.00 | $200.00K | $5.08B | $22.31M | $517.10M | $5.62B | 3 month · $64.13M | (m) | (m) | (m) | (m) |
| 2025-12-31 | $0.00 | $198.00K | $4.93B | $25.46M | $213.77M | $5.17B | 12 month · $249.35M | (m) | (m) | (m) | (m) |
| 2025-09-30 | $0.00 | $196.00K | $4.72B | $14.55M | $-85.51M | $4.65B | 3 month · $61.60M | (m) | (m) | (m) | (m) |
| 2025-06-30 | $0.00 | $194.00K | $4.67B | $13.44M | $-509.68M | $4.17B | 3 month · $64.61M | (m) | (m) | (m) | (m) |
| 2025-03-31 | $0.00 | $193.00K | $4.59B | $-6.24M | $-914.68M | $3.67B | 3 month · $60.98M | (m) | (m) | (m) | (m) |
| 2024-12-31 | $0.00 | $193.00K | $4.53B | $-13.12M | $-1.07B | $3.45B | 12 month · $266.06M | (m) | (m) | (m) | (m) |
| 2024-09-30 | $0.00 | $192.00K | $4.43B | $15.65M | $-1.27B | $3.17B | 3 month · $77.92M | (m) | (m) | (m) | (m) |
| 2024-06-30 | $0.00 | $191.00K | $4.38B | $-5.42M | $-1.38B | $3.00B | 3 month · $56.64M | 1 month · 60.00 | (m) | (m) | (m) |
| 2024-03-31 | $0.00 | $224.00K | $5.07B | $-6.17M | $329.93M | $5.39B | 3 month · $59.78M | (m) | (m) | (m) | (m) |
| 2023-12-31 | $0.00 | $224.00K | $5.02B | $13.11M | $160.38M | $5.19B | 12 month · $216.47M | (m) | (m) | (m) | (m) |
| 2023-09-30 | $0.00 | $224.00K | $4.95B | $22.89M | $-40.69M | $4.93B | 3 month · $48.00M | (m) | (m) | (m) | (m) |
| 2023-06-30 | $0.00 | $223.00K | $4.93B | $26.81M | $-211.96M | $4.74B | 3 month · $54.93M | (m) | (m) | (m) | (m) |
| 2023-03-31 | $0.00 | $223.00K | $4.86B | $20.94M | $-415.51M | $4.46B | 3 month · $53.56M | (m) | (m) | (m) | (m) |
| 2022-12-31 | $0.00 | $223.00K | $4.79B | $15.07M | $-437.21M | $4.37B | 12 month · $189.69M | (m) | (m) | (m) | (m) |
| 2022-09-30 | $0.00 | $222.00K | $4.72B | $-29.06M | $-465.68M | $4.23B | 3 month · $45.66M | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $222.00K | $4.69B | $-25.70M | $-578.45M | $4.09B | 3 month · $46.50M | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $221.00K | $4.63B | $-23.05M | $-739.88M | $3.86B | 3 month · $44.32M | (m) | (m) | (m) | (m) |
| 2021-12-31 | $0.00 | $221.00K | $4.57B | $-19.45M | $-777.87M | $3.77B | 12 month · $185.13M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $221.00K | $4.51B | $-18.65M | $-1.34B | $3.15B | 3 month · $43.31M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $220.00K | $4.48B | $-18.27M | $-1.52B | $2.94B | 3 month · $45.35M | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $220.00K | $4.42B | $-20.36M | $-1.67B | $2.73B | 3 month · $47.90M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $219.00K | $4.35B | $-15.36M | $-1.73B | $2.61B | 12 month · $178.53M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $219.00K | $4.28B | $-9.75M | $-1.88B | $2.39B | 3 month · $43.97M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $218.00K | $4.22B | $-12.42M | $-1.86B | $2.34B | 3 month · $46.41M | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $217.00K | $4.10B | $-13.11M | $-2.15B | $1.94B | 3 month · $42.76M | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $216.00K | $4.04B | $-15.54M | $-1.43B | $2.60B | 12 month · $167.03M | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $215.00K | $3.97B | $-8.61M | $-1.54B | $2.42B | 3 month · $43.47M | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $215.00K | $3.93B | $-8.96M | $-1.67B | $2.25B | 3 month · $40.71M | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $214.00K | $3.87B | $-9.25M | $-1.78B | $2.09B | 3 month · $40.69M | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $213.00K | $3.81B | $-10.16M | $-1.88B | $1.93B | 12 month · $148.27M | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $213.00K | $3.76B | $-9.52M | $-1.95B | $1.80B | 3 month · $38.00M | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $212.00K | $3.72B | $-9.81M | $-1.98B | $1.73B | 3 month · $36.60M | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $212.00K | $3.67B | $-10.12M | $-2.03B | $1.63B | 3 month · $36.22M | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $211.00K | $3.63B | $-7.01M | $-1.99B | $1.63B | 12 month · $133.06M | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | $211.00K | $3.59B | $12.51M | $-1.84B | $1.76B | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | $205.00K | $2.89B | $10.97M | $-1.88B | $1.03B | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | $205.00K | $2.82B | $5.38M | $-1.86B | $965.93M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $189.00K | $2.10B | $-2.89M | $-1.67B | $419.47M | 12 month · $96.20M | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | $188.00K | $2.05B | $390.00K | $-1.68B | $369.99M | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | $188.00K | $2.02B | $662.00K | $-1.72B | $297.06M | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | $187.00K | $1.98B | $397.00K | $-1.75B | $227.75M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $187.00K | $1.95B | $-809.00K | $-1.78B | $171.16M | 12 month · $69.87M | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | $186.00K | $1.92B | $-275.00K | $-1.83B | $88.74M | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | $180.00K | $1.85B | $1.95M | $-1.79B | $55.17M | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | $173.00K | $1.76B | $2.26M | $-1.80B | $-41.41M | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $171.00K | $1.70B | $1.81M | $-1.79B | $-81.63M | 12 month · $62.16M | (m) | (m) | (m) | 12 month · $-22.00K |
| 2014-09-30 | (m) | $169.00K | $1.66B | $1.91M | $-1.75B | $-89.59M | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | $168.00K | $1.63B | $2.08M | $-1.81B | $-171.00M | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | $167.00K | $1.61B | $2.04M | $-1.77B | $-162.42M | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $163.00K | $1.54B | $1.99M | $-1.74B | $-193.11M | 12 month · $38.40M | (m) | (m) | 12 month · $170.81M | 12 month · $214.00K |
| 2013-09-30 | (m) | $161.00K | $1.72B | $2.01M | $-1.69B | $28.79M | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | $153.00K | $1.64B | $1.99M | $-1.67B | $-27.79M | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | $136.00K | $1.50B | $2.00M | $-1.67B | $-163.53M | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | $133.00K | $1.48B | $1.88M | $-1.65B | $-174.96M | 12 month · $38.49M | (m) | (m) | (m) | (m) |
| 2012-09-30 | (m) | $131.00K | $1.45B | $2.15M | $-1.67B | $-219.95M | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | $130.00K | $1.43B | $1.72M | $-1.65B | $-217.19M | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | $128.00K | $1.40B | $1.94M | $-1.65B | $-248.86M | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | $126.00K | $1.38B | $1.64M | $-1.61B | $-227.08M | 12 month · $28.98M | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | $126.00K | $1.37B | $1.82M | $-1.55B | $-181.02M | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | $126.00K | $1.36B | $1.95M | $-1.50B | (m) | (m) | (m) | $-136.28M | (m) | (m) |
| 2011-03-31 | (m) | $124.00K | $1.34B | $2.09M | $-1.45B | (m) | (m) | (m) | $-103.98M | (m) | (m) |
| 2010-12-31 | (m) | $123.00K | $1.33B | $1.99M | $-1.42B | $-88.64M | 12 month · $14.86M | (m) | $-88.64M | (m) | (m) |
| 2009-12-31 | (m) | (m) | (m) | (m) | (m) | $-102.38M | 12 month · $9.98M | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | (m) | (m) | (m) | $-220.75M | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| IQVIA HOLDINGS INC. (IQV) | United States | $45.926B | 20.54 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B |